272 related articles for article (PubMed ID: 19136040)
1. The mucosal adjuvanticity of the oligodeoxynucleotides containing a non-methylated CpG motif on BCG and diphtheria toxoid.
Maeyama J; Komiya T; Takahashi M; Isaka M; Goto N; Yamamoto S
Vaccine; 2009 Feb; 27(8):1166-73. PubMed ID: 19136040
[TBL] [Abstract][Full Text] [Related]
2. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine.
Aguila A; Donachie AM; Peyre M; McSharry CP; Sesardic D; Mowat AM
Vaccine; 2006 Jun; 24(24):5201-10. PubMed ID: 16650917
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M
J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250
[TBL] [Abstract][Full Text] [Related]
4. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
Hickey DK; Aldwell FE; Beagley KW
Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotides as mucosal adjuvants.
Iho S; Maeyama J; Suzuki F
Hum Vaccin Immunother; 2015; 11(3):755-60. PubMed ID: 25751765
[TBL] [Abstract][Full Text] [Related]
6. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice.
Kohama H; Umemura M; Okamoto Y; Yahagi A; Goga H; Harakuni T; Matsuzaki G; Arakawa T
Vaccine; 2008 Feb; 26(7):924-32. PubMed ID: 18192091
[TBL] [Abstract][Full Text] [Related]
7. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
[TBL] [Abstract][Full Text] [Related]
8. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
Nyström-Asklin J; Adamsson J; Harandi AM
Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
10. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
[TBL] [Abstract][Full Text] [Related]
11. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx.
Abe N; Kodama S; Hirano T; Eto M; Suzuki M
Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899
[TBL] [Abstract][Full Text] [Related]
12. Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems.
Singh J; Pandit S; Bramwell VW; Alpar HO
Methods; 2006 Feb; 38(2):96-105. PubMed ID: 16442811
[TBL] [Abstract][Full Text] [Related]
13. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
[TBL] [Abstract][Full Text] [Related]
14. Induction of antibody responses in mice immunized intranasally with Type I interferon as adjuvant and synergistic effect of chitosan.
Maeyama JI; Kurata-Iesato Y; Isaka M; Komiya T; Sakurai S
Microbiol Immunol; 2020 Sep; 64(9):610-619. PubMed ID: 32662896
[TBL] [Abstract][Full Text] [Related]
15. Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice.
Ali R; Kumar S; Naqvi RA; Sheikh IA; Rao DN
Int Immunopharmacol; 2013 Jan; 15(1):97-105. PubMed ID: 23174507
[TBL] [Abstract][Full Text] [Related]
16. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity.
Kindrachuk J; Jenssen H; Elliott M; Townsend R; Nijnik A; Lee SF; Gerdts V; Babiuk LA; Halperin SA; Hancock RE
Vaccine; 2009 Jul; 27(34):4662-71. PubMed ID: 19539585
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and characterisation of A and B fragments of Corynebacterium diphtheriae toxin towards recombinant diphtheria vaccine.
Abulmagd S; Emara M; Aziz S; El-Domany R
Indian J Med Microbiol; 2013; 31(1):3-9. PubMed ID: 23508421
[TBL] [Abstract][Full Text] [Related]
18. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant.
Rydell N; Sjöholm I
Vaccine; 2004 Mar; 22(9-10):1265-74. PubMed ID: 15003656
[TBL] [Abstract][Full Text] [Related]
19. Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
Munro P; Flatau G; Lemichez E
Vaccine; 2007 Dec; 25(52):8702-6. PubMed ID: 18035455
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
